The purpose of this study is to determine if an investigational medication, QAW039, improves lung function in teens with uncontrolled asthma, compared to a placebo, a pill that does not contain the study medication.
The study also will determine if QAW039 has side effects, how serious they are, and how many times they happen compared to the placebo. QAW039 is a medication taken by mouth that works by blocking a receptor —a protein molecule that receives chemical signals from outside the cell— called DP2. When DP2 is blocked, blood cells that cause inflammation, such as eosinophils —a type of disease-fighting white blood cell— cannot move into the lungs and cause narrowed airways and asthma symptoms like wheezing and shortness of breath.
The Food and Drug Administration has not approved QAW039 for treatment of asthma. The investigational medication is not available for purchase or by prescription in the United States.